UroGen Pharma is trading at $40.82, down 4.54%, with the decline appearing aligned with broader risk-off trading rather than a confirmed company-specific catalyst.
- No new company-specific announcement was listed through September 23, 2026; the latest release was dated September 4, 2026.
- The Nasdaq fell 0.78%, while Treasury yields rose.
- Trading volume data was unavailable, so activity cannot be assessed.